Collegium Pharmaceutical Inc [COLL] stock is trading at $34.52, down -5.06%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The COLL shares have lost -1.06% over the last week, with a monthly amount glided 7.27%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Collegium Pharmaceutical Inc [NASDAQ: COLL] stock has seen the most recent analyst activity on July 30, 2024, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $47 for it. Previously, Jefferies upgraded its rating to Buy on June 07, 2024, and elevated its price target to $44. On May 10, 2024, downgrade downgraded it’s rating to Neutral but maintained its price target of $39 on the stock. Needham downgraded its rating to a Hold. Jefferies downgraded its rating to a Hold and raised its price target to $37 on January 04, 2024. Needham reiterated a Buy rating for this stock on August 25, 2023, and upped its price target to $36.
Collegium Pharmaceutical Inc [COLL] stock has fluctuated between $20.95 and $40.95 over the past year. Currently, Wall Street analysts expect the stock to reach $41.25 within the next 12 months. Collegium Pharmaceutical Inc [NASDAQ: COLL] shares were valued at $34.52 at the most recent close of the market. An investor can expect a potential return of 19.5% based on the average COLL price forecast.
Analyzing the COLL fundamentals
Collegium Pharmaceutical Inc [NASDAQ:COLL] reported sales of 566.92M for the trailing twelve months, which represents a growth of 0.11%. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at 0.34%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.47 and Total Capital is 0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.81.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.53 points at the first support level, and at 32.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.65, and for the 2nd resistance point, it is at 36.79.
Ratios To Look Out For
For context, Collegium Pharmaceutical Inc’s Current Ratio is 1.21. Further, the Quick Ratio stands at 1.14, while the Cash Ratio is 0.51. Considering the valuation of this stock, the price to sales ratio is 1.99, the price to book ratio is 5.08 and price to earnings (TTM) ratio is 14.38.
Transactions by insiders
Recent insider trading involved Kuhlmann Shirley R., EVP and General Counsel, that happened on Jun 03 ’24 when 25000.0 shares were sold. EVP & Chief Financial Officer, Tupper Colleen completed a deal on May 28 ’24 to sell 19710.0 shares. Meanwhile, EVP & Chief Commercial Officer Dreyer Scott sold 56807.0 shares on May 24 ’24.
